Goldman-backed biotech firm Ascletis becomes first to apply for HK IPO under new rules

Chinese biotechnology firm Ascletis Pharma becomes the first biotech company to apply for an initial public offering (IPO) in Hong Kong after the exchange implemented new, more relaxed listing rules that allow biotech firms to list even if they still have not made profit or revenue.